Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount

Novo Nordisk has revised down its full-year sales growth guidance to 8-11% and operating profit growth to 4-7% at constant exchange rates, attributing the adjustment to intensifying competition, pricing pressures, and evolving prescription trends in the obesity and diabetes market. This marks the fourth guidance reduction this year, occurring despite robust Wegovy sales that slightly missed analyst expectations, and coincides with a significant share price decline and a contested $10 billion acquisition bid for Metsera amid a legal challenge from Pfizer, underscoring a challenging competitive landscape for the pharmaceutical leader.

Analysis

Novo Nordisk (NVO) has lowered its full-year sales growth guidance for the fourth time to 8-11% (from 8-14%) and operating profit growth to 4-7% (from 4-10%) at constant exchange rates. This revision is attributed to intensifying competition, pricing pressures, and evolving prescription trends in the obesity and diabetes market. Despite this, net profit of 20 billion DKK ($3.1 billion) was in line with analyst expectations, and Wegovy sales rose 18% year-on-year to 20.35 billion DKK, though slightly below forecasts.

The company's Copenhagen-listed shares have tumbled over 50% year-to-date, reflecting investor concerns over multiple headwinds. These include disappointing trial results, increasing competition in the GLP-1 space, U.S. drug pricing challenges, and leadership changes. Analyst sentiment is mixed, with Jefferies cutting its rating to Underperform, while Berenberg maintains a positive outlook, citing NVO's superior growth profile and R&D returns.

Novo Nordisk is actively pursuing strategic growth, evidenced by its revised $10 billion bid for American obesity biotech firm Metsera (MTSR), which Metsera deemed "superior" to Pfizer's (PFE) offer. This acquisition attempt, however, faces a second lawsuit from Pfizer alleging anticompetitive practices, which NVO denies. The company also noted the acquisition of Akero Therapeutics (AKRO) and ongoing development of another weight management drug, signaling a commitment to innovation amidst market dynamics.

Key Decisions for Investors

• Closely monitor Novo Nordisk's execution against its lowered full-year guidance, as continued competitive pressures or pricing erosion could further impact profitability.
• Assess the strategic implications and legal risks associated with the Metsera acquisition, particularly Pfizer's antitrust lawsuit, for NVO's long-term growth trajectory and market dominance in the GLP-1 segment.
• Re-evaluate NVO's valuation premium in light of increased market uncertainty, considering both its robust R&D pipeline and the intensifying competitive and regulatory headwinds.